CURRICULUM VITAE
HEIDELINDE FIEGL

1. Personal details

Personal details:

Name:	Heidelinde Fiegl
Date of Birth:	14.06.1975
Place of Birth:	Innsbruck, Austria
Nationality:	Austrian
Title:	PhD, MSc

Current address and position:

Medical University of Innsbruck
Department of Obstetrics and Gynecology
Anichstr. 35
A-6020 Innsbruck
Austria
Tel: 0043(0) 512 504 23113
FAX: 0043(0) 512 504 23112
Mail: Heidelinde.Fiegl@i-med.ac.at
Associate Professor, Head of the Laboratory for Clinical Biochemistry

1.1 Education

July 2001	Ph.D degree; (result: pass with distinction).
November 1998	Start of PhD thesis "Identification and characterization of a new member of the immunoglobulin superfamily differentially expressed on human Dendritic cells during maturation" at the Dept. of Dermatology and Venerology, University of Innsbruck under the guidance of Univ. Prof. Dr. Christine Heufler-Tiefenthaler.
October 1998	Award of the diploma Mag.rer.nat (Master of Science) from the University of Innsbruck. (result: pass with distinction).
1997 – 1998	Master thesis "Differential description of transcribed genes of the human dendritic cell in two different maturation stages." at the Dept. of Dermatology and Venerology, University of Innsbruck under the guidance of Univ. Prof. Dr. Christine Heufler-Tiefenthaler.
1993 – 1998	Study of microbiology at the Leopold Franzens University of Innsbruck, with main focus on molecular biology and biochemistry.

1.2 Specialization

October 2008	Awarded venia docendi for Experimental Gynecology by the Medical University of Innsbruck (MUI)

1.3 Professional Experience

Since August 2014	Univ. Assoc. Prof. at the Dept. of Obstetrics and Gynecology; MUI.
Since December 2011	Univ. Ass. Prof. at the Dept. of Obstetrics and Gynecology; MUI.
Since October 2010	Head of the Laboratory for Clinical Biochemistry, Dept. of Obstetrics and Gynecology; Medical University of Innsbruck. (responsible person for the clinical routine laboratory and the research laboratory)
April 2009	Univ. Ass. at the Dept. of Obstetrics and Gynecology; MUI.
Aug 2007 – March 2009	Senior Postdoc at the Dept. of Obstetrics and Gynecology; MUI.
July 2006 – July 2007	Senior Postdoc at the Tyrolean Cancer Research Institute
Nov 2005 – June 2006	Senior Postdoc in the work group of Prof. Dr. Martin Widschwendter; Institute of Women's Health, Dept. of Gynecological Oncology; University College London.
2001 –2005	Postdoctoral fellowship with Prof. Dr. Martin Widschwendter; Dept. of Obstetrics and Gynecology; MUI.

2. Research

2.1 Research focus:

- Epigenetic aberrations in breast and ovarian cancer
- Identification of biomarkers to facilitate risk prediction and individualization of cancer treatment in female malignancies.

2.2 Publications

2.2.1 Metrics

Number of publication:	83	
Impact factor points:	517.78	total; 80 Original papers, 3 Reviews;
	141.65	leading author
number of citations:	4095 (without self-citations: 3993)	
	3450 citing articles, 3400 citing articles without self-citations	
Average citations per item:	37.57	
Hirsch Factor Index:	33	
G-Factor Index:	63	

2.2.2 Selected publications (last 10 years)

1. **Fiegl H**, Jones A, Hauser-Kronberger C, et.al. Methylated *NEUROD1* promoter is a marker for chemosensitivity in breast cancer. Clin. Cancer Res. 2008;14(11):3494-502.
2. **Fiegl H**, Windbichler G, Mueller-Holzner E, et al. *HOXA11* DNA Methylation - A Novel Prognostic Biomarker in Ovarian Cancer. Int J Cancer. 2008;123(3):725-9.
3. Berger R*, **Fiegl H*,** Goebel G, et al. Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci. 2010;101(4):1059-66.
4. Zeimet AG, **Fiegl H*,** Goebel G, Kopp F, Allasia C, Reimer D, Steppan I, Mueller-Holzner A, Ehrlich M, Marth C. DNA ploidy, nuclear size, proliferation index and DNA hypomethylation
5. Goebel G, Berger R, Strasak AM, Egle D, Müller-Holzner E, Schmidt S, Rainer J, Presul E, Parson W, Lang S, Jones A, Widschwendter M, **Fiegl H**. Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients. Br J Cancer. 2012;106(1):189-98.
6. Lirk P, Berger R, Hollmann MW, **Fiegl H.** Lidocaine time- and dose-dependently demethylates DNA in breast cancer cell lines in vitro. Br J Anaesth. 2012;109(2):200-7.
7. Abudukadeer A, Bakry R, Goebel G, Mutz-Dehbalaie I, Widschwendter A, **Fiegl H.** Clinical relevance of *CDH1* and *CDH13* DNA methylation in serum of cervical cancer patients. Int. J. Mol. Sci. 2012;13(7): 8353-8363.
8. Jones A, Teschendorff A, Li Q, Hayward J, Kannan A, Mould T, West J, Zikan M, Cibula D, **Fiegl H**, et al. Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development. PLoS Med. 2013;10(11):e1001551.
9. Lirk P, Hollmann MW, Fleischer M, Weber N, **Fiegl H**. In vitro, lidocaine, but not bupivacaine or ropivacaine, increases the demethylating effects of 5-aza-2'-deoxycytidine. Br J Anaesth. 2014. Suppl 1:i32-8.
10. Ratzinger G, Millinger S, Wolf B, Zelger B, Weinlich G, Fritsch P, Ratzinger G, Goebel G, **Fiegl H**. *TNFRSF10D* DNA methylation in melanoma. Int J Mol Sci. 2014;15(7):11984-95.
11. Teschendorff AE, Lee SH, Jones A, **Fiegl H**, et al. HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. Genome Med. 2015;7(1):108.
12. Wolf B, Goebel G, Hackl H, **Fiegl H**. Reduced mRNA expression levels of *NFE2L2* are associated with poor outcome in breast cancer patients. BMC Cancer. 2016;16(1):821.
13. Pölsler L*, **Fiegl H***, Wimmer K, et al. High prevalence of *BRCA1* stop mutation c.4183C>T in the Tyrolean population: Implications for genetic testing. Eur J Hum Genet. 2016;24(2):258-62.
14. Tomar T, Alkema NG, Schreuder L, Meersma GJ, de Meyer T, van Criekinge W, Klip HG, **Fiegl H**, et al. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. BMC Med. 2017;15(1):116.
15. Wieser V, Gaugg I, Fleischer M, Shivalingaiah G, Wenzel S, Sprung S, Lax S, Zeimet AG, **Fiegl H***, Marth C*. *BRCA1/2* and *TP53* mutation status associates with *PD-1* and *PD-L1* expression in ovarian cancer. Oncotarget, doi.org/10.18632/oncotarget.24770

*** The authors contributed equally to this work**